🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against superbug strains of the pathogen, according to scientists.

An International Health Concern

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million infections each year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Secure Clearance

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm Innoviva to see it through.

“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

Based on findings detailed in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research included over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in many regions with limited resources.

Doctors treating patients have voiced positive views. The availability of a one-pill regimen like this is described as a "revolutionary step" for public health efforts. This is deemed vital to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.